ADMA Biologics, Inc. (ADMA): Total Assets
$624.24M
As of 2025-12-31
$684.21M
As of 2026-06-30
+21.5%
3-year compound annual growth
+24.6%
5-year compound annual growth
+38.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $624.24M | +27.7% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $488.68M | +48.5% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $329.18M | -5.5% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $348.46M | +26.1% | 2025-03-18, Balance as of period end |
| 2021-12-31 | $276.25M | +33.0% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $207.67M | +63.4% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $127.09M | +43.0% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $88.88M | -17.7% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $108.02M | +356.1% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $23.69M | -0.1% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $23.71M | -12.2% | 2017-02-24, Balance as of period end |
| 2014-12-31 | $27.02M | -15.5% | 2016-03-23, Balance as of period end |
| 2013-12-31 | $31.98M | +105.6% | 2015-03-09, Balance as of period end |
| 2012-12-31 | $15.56M | +431.6% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $2.93M | n/a | 2013-03-06, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $624.24M | +27.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $562.16M | +49.1% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $1.07B | +5.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.33B | +26.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $641.86M | +4.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $512.74M | -4.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗